|
JUNE 17th, 2005
Martin Nutraceuticals Inc. (Pink Sheets:MTNU) indicates that new
research indicates that Pine Bark Extract, the main active ingredient in the company’s Oxygenol product may be
helpful in the treatment of asthma.
Dr. A.W. Martin DC, Ph.D., RNCP, DNM, Director of Research at Martin
Nutraceuticals referenced a double blind placebo study published in the Nov/Dec 2004 issue of Journal of Asthma, "found that
60 children aged 6-18 were able to significantly reduce or discontinue their use of rescue inhalers with Pine Bark Extract,
more specifically Pycnogenol, more often than the placebo group."
JUNE 10th, 2005
Critical Therapeutics Sets up Private Placement Agreements
- Expects $54.5 Million in June
Critical Therapeutics, Inc. (NASDAQ: CRTX) in an arrangement that involves institutional investors,
accredited investors, existing stockholders and affiliated entities, has entered into a definitive agreements whereby the
company will place approximately 9.9 million shares of its common stock at $5.48 per share. With the added help of warrants,
the company expects to raise about $54.5 from the transaction, which is scheduled to close on or about June 20, 2005.
With the net proceeds, the company plans to launch its investigational
asthma drug ZYFLO Filmtab (zileuton tablets) The launch of the product is contingent on the company obtaining pending regulatory
approval of a supplemental New Drug Application. Other plans include the further development of the company’s other
products and the expansion of its drug discovery efforts.
JUNE 7th, 2005
As new technology emerges from the semiconductor and nanotechnology
worlds, minimally invasive is expected to be a phrase one sees more often in the medical world. Electromagnetics, low -cost
advanced imaging technologies, nanodrugs, and miniature micromachined devices all have the potential to make non-invasive
medicine a reality.
Venture capitalists also have an interest in minimally invasive
companies. superDimension Ltd. for instance recently completed a Series B round valued at $27 million. The investment was
led by OrbiMed Advisors LLC, CIBC World Markets and the Strategic Investments Group of Pfizer, Inc. Other existing investors
included Mi3. Other investors superDimension listed were Oxford Bioscience Partners, Pitango Venture Capital, Medica Venture
Partners and Mi3.
Jonathan Silverstein, General Partner at OrbiMed gave his analysis
of superDimension's minimally invasive product, "In our estimation, superDimension is the best medical device platform in
the emerging field of interventional pulmonology. The superDimension system provides a quantum leap forward in a pulmonologist's
ability to successfully biopsy distal tissue in the lungs. In the future, we believe the Bronchus platform will enable doctors
to not only diagnose, but treat patients with pulmonary disease. By providing a new 'railroad' to distal regions of the lung,
superDimension will enable new treatment methodologies that should be more effective and less invasive. We look forward to
working with superDimension's management and board to make this company a commercial success." Concurrent with the closing
of the financing, Mr. Silverstein will join the board of directors of superDimension.
superDimension's states that its platform is based on electromagnetic
localization, image processing, image-to-body registration and steerable endoscopic tools.
|
